Table of Content

1 Report Overview
1.1 Axial Spondyloarthritis Drugs Definition
1.2 Market by Type
1.2.1 Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Certolizumab Pegol
1.2.3 Etanercept Biosimilar
1.2.4 Ixekizumab
1.2.5 Secukinumab
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Axial Spondyloarthritis Drugs Sales
2.1 Global Axial Spondyloarthritis Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Axial Spondyloarthritis Drugs Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Axial Spondyloarthritis Drugs Revenue by Region
2.3.1 Global Axial Spondyloarthritis Drugs Revenue by Region (2018-2023)
2.3.2 Global Axial Spondyloarthritis Drugs Revenue by Region (2024-2034)
2.4 Global Axial Spondyloarthritis Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Axial Spondyloarthritis Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Axial Spondyloarthritis Drugs Sales Quantity by Region
2.6.1 Global Axial Spondyloarthritis Drugs Sales Quantity by Region (2018-2023)
2.6.2 Global Axial Spondyloarthritis Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Axial Spondyloarthritis Drugs Sales Quantity by Manufacturers
3.1.1 Global Axial Spondyloarthritis Drugs Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Axial Spondyloarthritis Drugs Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Axial Spondyloarthritis Drugs Sales in 2024
3.2 Global Axial Spondyloarthritis Drugs Revenue by Manufacturers
3.2.1 Global Axial Spondyloarthritis Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Axial Spondyloarthritis Drugs Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Axial Spondyloarthritis Drugs Revenue in 2024
3.3 Global Axial Spondyloarthritis Drugs Sales Price by Manufacturers
3.4 Global Key Players of Axial Spondyloarthritis Drugs, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Axial Spondyloarthritis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Axial Spondyloarthritis Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Axial Spondyloarthritis Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Axial Spondyloarthritis Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Axial Spondyloarthritis Drugs Sales Quantity by Type
4.1.1 Global Axial Spondyloarthritis Drugs Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Axial Spondyloarthritis Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Axial Spondyloarthritis Drugs Revenue by Type
4.2.1 Global Axial Spondyloarthritis Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Axial Spondyloarthritis Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Axial Spondyloarthritis Drugs Price by Type
4.3.1 Global Axial Spondyloarthritis Drugs Price by Type (2018-2023)
4.3.2 Global Axial Spondyloarthritis Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Axial Spondyloarthritis Drugs Sales Quantity by Application
5.1.1 Global Axial Spondyloarthritis Drugs Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Axial Spondyloarthritis Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Axial Spondyloarthritis Drugs Revenue by Application
5.2.1 Global Axial Spondyloarthritis Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Axial Spondyloarthritis Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Axial Spondyloarthritis Drugs Price by Application
5.3.1 Global Axial Spondyloarthritis Drugs Price by Application (2018-2023)
5.3.2 Global Axial Spondyloarthritis Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Axial Spondyloarthritis Drugs Sales by Company
6.1.1 North America Axial Spondyloarthritis Drugs Revenue by Company (2018-2023)
6.1.2 North America Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023)
6.2 North America Axial Spondyloarthritis Drugs Market Size by Type
6.2.1 North America Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Axial Spondyloarthritis Drugs Revenue by Type (2018-2034)
6.3 North America Axial Spondyloarthritis Drugs Market Size by Application
6.3.1 North America Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Axial Spondyloarthritis Drugs Revenue by Application (2018-2034)
6.4 North America Axial Spondyloarthritis Drugs Market Size by Country
6.4.1 North America Axial Spondyloarthritis Drugs Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Axial Spondyloarthritis Drugs Revenue by Country (2018-2034)
6.4.3 North America Axial Spondyloarthritis Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Axial Spondyloarthritis Drugs Sales by Company
7.1.1 Europe Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023)
7.1.2 Europe Axial Spondyloarthritis Drugs Revenue by Company (2018-2023)
7.2 Europe Axial Spondyloarthritis Drugs Market Size by Type
7.2.1 Europe Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Axial Spondyloarthritis Drugs Revenue by Type (2018-2034)
7.3 Europe Axial Spondyloarthritis Drugs Market Size by Application
7.3.1 Europe Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Axial Spondyloarthritis Drugs Revenue by Application (2018-2034)
7.4 Europe Axial Spondyloarthritis Drugs Market Size by Country
7.4.1 Europe Axial Spondyloarthritis Drugs Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Axial Spondyloarthritis Drugs Revenue by Country (2018-2034)
7.4.3 Europe Axial Spondyloarthritis Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Axial Spondyloarthritis Drugs Sales by Company
8.1.1 China Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023)
8.1.2 China Axial Spondyloarthritis Drugs Revenue by Company (2018-2023)
8.2 China Axial Spondyloarthritis Drugs Market Size by Type
8.2.1 China Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Axial Spondyloarthritis Drugs Revenue by Type (2018-2034)
8.3 China Axial Spondyloarthritis Drugs Market Size by Application
8.3.1 China Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Axial Spondyloarthritis Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Axial Spondyloarthritis Drugs Sales by Company
9.1.1 APAC Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023)
9.1.2 APAC Axial Spondyloarthritis Drugs Revenue by Company (2018-2023)
9.2 APAC Axial Spondyloarthritis Drugs Market Size by Type
9.2.1 APAC Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Axial Spondyloarthritis Drugs Revenue by Type (2018-2034)
9.3 APAC Axial Spondyloarthritis Drugs Market Size by Application
9.3.1 APAC Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Axial Spondyloarthritis Drugs Revenue by Application (2018-2034)
9.4 APAC Axial Spondyloarthritis Drugs Market Size by Region
9.4.1 APAC Axial Spondyloarthritis Drugs Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Axial Spondyloarthritis Drugs Revenue by Region (2018-2034)
9.4.3 APAC Axial Spondyloarthritis Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Company Information
11.1.2 AstraZeneca Plc Overview
11.1.3 AstraZeneca Plc Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Products and Services
11.1.5 AstraZeneca Plc Axial Spondyloarthritis Drugs SWOT Analysis
11.1.6 AstraZeneca Plc Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Information
11.2.2 Eli Lilly and Company Overview
11.2.3 Eli Lilly and Company Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Eli Lilly and Company Axial Spondyloarthritis Drugs Products and Services
11.2.5 Eli Lilly and Company Axial Spondyloarthritis Drugs SWOT Analysis
11.2.6 Eli Lilly and Company Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Information
11.3.2 Johnson & Johnson Overview
11.3.3 Johnson & Johnson Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Johnson & Johnson Axial Spondyloarthritis Drugs Products and Services
11.3.5 Johnson & Johnson Axial Spondyloarthritis Drugs SWOT Analysis
11.3.6 Johnson & Johnson Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Novartis AG Axial Spondyloarthritis Drugs Products and Services
11.4.5 Novartis AG Axial Spondyloarthritis Drugs SWOT Analysis
11.4.6 Novartis AG Recent Developments
11.5 Panacea Biotec Ltd
11.5.1 Panacea Biotec Ltd Company Information
11.5.2 Panacea Biotec Ltd Overview
11.5.3 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Products and Services
11.5.5 Panacea Biotec Ltd Axial Spondyloarthritis Drugs SWOT Analysis
11.5.6 Panacea Biotec Ltd Recent Developments
11.6 Sandoz International GmbH
11.6.1 Sandoz International GmbH Company Information
11.6.2 Sandoz International GmbH Overview
11.6.3 Sandoz International GmbH Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Sandoz International GmbH Axial Spondyloarthritis Drugs Products and Services
11.6.5 Sandoz International GmbH Axial Spondyloarthritis Drugs SWOT Analysis
11.6.6 Sandoz International GmbH Recent Developments
11.7 Sun Pharma Advanced Research Company Ltd
11.7.1 Sun Pharma Advanced Research Company Ltd Company Information
11.7.2 Sun Pharma Advanced Research Company Ltd Overview
11.7.3 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Products and Services
11.7.5 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs SWOT Analysis
11.7.6 Sun Pharma Advanced Research Company Ltd Recent Developments
11.8 UCB SA
11.8.1 UCB SA Company Information
11.8.2 UCB SA Overview
11.8.3 UCB SA Axial Spondyloarthritis Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 UCB SA Axial Spondyloarthritis Drugs Products and Services
11.8.5 UCB SA Axial Spondyloarthritis Drugs SWOT Analysis
11.8.6 UCB SA Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Axial Spondyloarthritis Drugs Value Chain Analysis
12.2 Axial Spondyloarthritis Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Axial Spondyloarthritis Drugs Production Mode & Process
12.4 Axial Spondyloarthritis Drugs Sales and Marketing
12.4.1 Axial Spondyloarthritis Drugs Sales Channels
12.4.2 Axial Spondyloarthritis Drugs Distributors
12.5 Axial Spondyloarthritis Drugs Customers
13 Market Dynamics
13.1 Axial Spondyloarthritis Drugs Industry Trends
13.2 Axial Spondyloarthritis Drugs Market Drivers
13.3 Axial Spondyloarthritis Drugs Market Challenges
13.4 Axial Spondyloarthritis Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Axial Spondyloarthritis Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Certolizumab Pegol
Table 3. Major Manufacturers of Etanercept Biosimilar
Table 4. Major Manufacturers of Ixekizumab
Table 5. Major Manufacturers of Secukinumab
Table 6. Major Manufacturers of Others
Table 7. Global Axial Spondyloarthritis Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Axial Spondyloarthritis Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Axial Spondyloarthritis Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2018-2023)
Table 11. Global Axial Spondyloarthritis Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2024-2034)
Table 13. Global Axial Spondyloarthritis Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 14. Global Axial Spondyloarthritis Drugs Sales by Region (2018-2023) & (K Pcs)
Table 15. Global Axial Spondyloarthritis Drugs Sales Market Share by Region (2018-2023)
Table 16. Global Axial Spondyloarthritis Drugs Sales by Region (2024-2034) & (K Pcs)
Table 17. Global Axial Spondyloarthritis Drugs Sales Market Share by Region (2024-2034)
Table 18. Global Axial Spondyloarthritis Drugs Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 19. Global Axial Spondyloarthritis Drugs Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Axial Spondyloarthritis Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Axial Spondyloarthritis Drugs Revenue Share by Manufacturers (2018-2023)
Table 22. Global Axial Spondyloarthritis Drugs Price by Manufacturers 2018-2023 (USD/Pcs)
Table 23. Global Key Players of Axial Spondyloarthritis Drugs, Industry Ranking, 2021 VS 2024
Table 24. Global Axial Spondyloarthritis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Axial Spondyloarthritis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Axial Spondyloarthritis Drugs as of 2024)
Table 26. Global Key Manufacturers of Axial Spondyloarthritis Drugs, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Axial Spondyloarthritis Drugs, Product Offered and Application
Table 28. Global Key Manufacturers of Axial Spondyloarthritis Drugs, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 31. Global Axial Spondyloarthritis Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 32. Global Axial Spondyloarthritis Drugs Sales Quantity Share by Type (2018-2023)
Table 33. Global Axial Spondyloarthritis Drugs Sales Quantity Share by Type (2024-2034)
Table 34. Global Axial Spondyloarthritis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Axial Spondyloarthritis Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Axial Spondyloarthritis Drugs Revenue Share by Type (2018-2023)
Table 37. Global Axial Spondyloarthritis Drugs Revenue Share by Type (2024-2034)
Table 38. Axial Spondyloarthritis Drugs Price by Type (2018-2023) & (USD/Pcs)
Table 39. Global Axial Spondyloarthritis Drugs Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 40. Global Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 41. Global Axial Spondyloarthritis Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 42. Global Axial Spondyloarthritis Drugs Sales Quantity Share by Application (2018-2023)
Table 43. Global Axial Spondyloarthritis Drugs Sales Quantity Share by Application (2024-2034)
Table 44. Global Axial Spondyloarthritis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Axial Spondyloarthritis Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Axial Spondyloarthritis Drugs Revenue Share by Application (2018-2023)
Table 47. Global Axial Spondyloarthritis Drugs Revenue Share by Application (2024-2034)
Table 48. Axial Spondyloarthritis Drugs Price by Application (2018-2023) & (USD/Pcs)
Table 49. Global Axial Spondyloarthritis Drugs Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 50. North America Axial Spondyloarthritis Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 52. North America Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 53. North America Axial Spondyloarthritis Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 54. North America Axial Spondyloarthritis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Axial Spondyloarthritis Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 57. North America Axial Spondyloarthritis Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 58. North America Axial Spondyloarthritis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Axial Spondyloarthritis Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Axial Spondyloarthritis Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Axial Spondyloarthritis Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Axial Spondyloarthritis Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Axial Spondyloarthritis Drugs Sales Quantity by Country (2018-2023) & (K Pcs)
Table 64. North America Axial Spondyloarthritis Drugs Sales Quantity by Country (2024-2034) & (K Pcs)
Table 65. Europe Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 66. Europe Axial Spondyloarthritis Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 68. Europe Axial Spondyloarthritis Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 69. Europe Axial Spondyloarthritis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Axial Spondyloarthritis Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 72. Europe Axial Spondyloarthritis Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 73. Europe Axial Spondyloarthritis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Axial Spondyloarthritis Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Axial Spondyloarthritis Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Axial Spondyloarthritis Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Axial Spondyloarthritis Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Axial Spondyloarthritis Drugs Sales Quantity by Country (2018-2023) & (K Pcs)
Table 79. Europe Axial Spondyloarthritis Drugs Sales Quantity by Country (2024-2034) & (K Pcs)
Table 80. China Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 81. China Axial Spondyloarthritis Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 83. China Axial Spondyloarthritis Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 84. China Axial Spondyloarthritis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Axial Spondyloarthritis Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 87. China Axial Spondyloarthritis Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 88. China Axial Spondyloarthritis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Axial Spondyloarthritis Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 91. APAC Axial Spondyloarthritis Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 93. APAC Axial Spondyloarthritis Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 94. APAC Axial Spondyloarthritis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Axial Spondyloarthritis Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 97. APAC Axial Spondyloarthritis Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 98. APAC Axial Spondyloarthritis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Axial Spondyloarthritis Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Axial Spondyloarthritis Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Axial Spondyloarthritis Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Axial Spondyloarthritis Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Axial Spondyloarthritis Drugs Sales Quantity by Region (2018-2023) & (K Pcs)
Table 104. APAC Axial Spondyloarthritis Drugs Sales Quantity by Region (2024-2034) & (K Pcs)
Table 105. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Company (2018-2023) & (K Pcs)
Table 106. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Type (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Type (2024-2034) & (K Pcs)
Table 109. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Application (2018-2023) & (K Pcs)
Table 112. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Application (2024-2034) & (K Pcs)
Table 113. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Country (2018-2023) & (K Pcs)
Table 119. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity by Country (2024-2034) & (K Pcs)
Table 120. AstraZeneca Plc Company Information
Table 121. AstraZeneca Plc Description and Overview
Table 122. AstraZeneca Plc Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 123. AstraZeneca Plc Axial Spondyloarthritis Drugs Product and Services
Table 124. AstraZeneca Plc Axial Spondyloarthritis Drugs SWOT Analysis
Table 125. AstraZeneca Plc Recent Developments
Table 126. Eli Lilly and Company Company Information
Table 127. Eli Lilly and Company Description and Overview
Table 128. Eli Lilly and Company Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 129. Eli Lilly and Company Axial Spondyloarthritis Drugs Product and Services
Table 130. Eli Lilly and Company Axial Spondyloarthritis Drugs SWOT Analysis
Table 131. Eli Lilly and Company Recent Developments
Table 132. Johnson & Johnson Company Information
Table 133. Johnson & Johnson Description and Overview
Table 134. Johnson & Johnson Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 135. Johnson & Johnson Axial Spondyloarthritis Drugs Product and Services
Table 136. Johnson & Johnson Axial Spondyloarthritis Drugs SWOT Analysis
Table 137. Johnson & Johnson Recent Developments
Table 138. Novartis AG Company Information
Table 139. Novartis AG Description and Overview
Table 140. Novartis AG Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 141. Novartis AG Axial Spondyloarthritis Drugs Product and Services
Table 142. Novartis AG Axial Spondyloarthritis Drugs SWOT Analysis
Table 143. Novartis AG Recent Developments
Table 144. Panacea Biotec Ltd Company Information
Table 145. Panacea Biotec Ltd Description and Overview
Table 146. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 147. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Product and Services
Table 148. Panacea Biotec Ltd Axial Spondyloarthritis Drugs SWOT Analysis
Table 149. Panacea Biotec Ltd Recent Developments
Table 150. Sandoz International GmbH Company Information
Table 151. Sandoz International GmbH Description and Overview
Table 152. Sandoz International GmbH Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 153. Sandoz International GmbH Axial Spondyloarthritis Drugs Product and Services
Table 154. Sandoz International GmbH Axial Spondyloarthritis Drugs SWOT Analysis
Table 155. Sandoz International GmbH Recent Developments
Table 156. Sun Pharma Advanced Research Company Ltd Company Information
Table 157. Sun Pharma Advanced Research Company Ltd Description and Overview
Table 158. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 159. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Product and Services
Table 160. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs SWOT Analysis
Table 161. Sun Pharma Advanced Research Company Ltd Recent Developments
Table 162. UCB SA Company Information
Table 163. UCB SA Description and Overview
Table 164. UCB SA Axial Spondyloarthritis Drugs Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 165. UCB SA Axial Spondyloarthritis Drugs Product and Services
Table 166. UCB SA Axial Spondyloarthritis Drugs SWOT Analysis
Table 167. UCB SA Recent Developments
Table 168. Key Raw Materials Lists
Table 169. Raw Materials Key Suppliers Lists
Table 170. Axial Spondyloarthritis Drugs Distributors List
Table 171. Axial Spondyloarthritis Drugs Customers List
Table 172. Axial Spondyloarthritis Drugs Market Trends
Table 173. Axial Spondyloarthritis Drugs Market Drivers
Table 174. Axial Spondyloarthritis Drugs Market Challenges
Table 175. Axial Spondyloarthritis Drugs Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Axial Spondyloarthritis Drugs Product Picture
Figure 2. Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Axial Spondyloarthritis Drugs Market Share by Type in 2024 & 2034
Figure 4. Certolizumab Pegol Product Picture
Figure 5. Etanercept Biosimilar Product Picture
Figure 6. Ixekizumab Product Picture
Figure 7. Secukinumab Product Picture
Figure 8. Others Product Picture
Figure 9. Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Axial Spondyloarthritis Drugs Market Share by Application in 2024 & 2034
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Home Care
Figure 14. Axial Spondyloarthritis Drugs Report Years Considered
Figure 15. Global Axial Spondyloarthritis Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Axial Spondyloarthritis Drugs Revenue 2018-2034 (US$ Million)
Figure 17. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 18. Global Axial Spondyloarthritis Drugs Sales Quantity 2018-2034 (K Pcs)
Figure 19. Global Axial Spondyloarthritis Drugs Sales Quantity Market Share by Region (2018-2023)
Figure 20. Global Axial Spondyloarthritis Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Axial Spondyloarthritis Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 22. North America Axial Spondyloarthritis Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Axial Spondyloarthritis Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. Europe Axial Spondyloarthritis Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Axial Spondyloarthritis Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. China Axial Spondyloarthritis Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Axial Spondyloarthritis Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. APAC Axial Spondyloarthritis Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Axial Spondyloarthritis Drugs Sales Quantity in 2024
Figure 32. The Top 10 and Top 5 Players Market Share by Axial Spondyloarthritis Drugs Revenue in 2024
Figure 33. Axial Spondyloarthritis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 34. Global Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
Figure 36. Global Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
Figure 38. North America Axial Spondyloarthritis Drugs Revenue Market Share by Company in 2024
Figure 39. North America Axial Spondyloarthritis Drugs Sales Quantity Market Share by Company in 2024
Figure 40. North America Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
Figure 42. North America Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
Figure 44. North America Axial Spondyloarthritis Drugs Revenue Share by Country (2018-2034)
Figure 45. North America Axial Spondyloarthritis Drugs Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Axial Spondyloarthritis Drugs Sales Quantity Market Share by Company in 2024
Figure 49. Europe Axial Spondyloarthritis Drugs Revenue Market Share by Company in 2024
Figure 50. Europe Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
Figure 52. Europe Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
Figure 54. Europe Axial Spondyloarthritis Drugs Revenue Share by Country (2018-2034)
Figure 55. Europe Axial Spondyloarthritis Drugs Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. France Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. China Axial Spondyloarthritis Drugs Sales Quantity Market Share by Company in 2024
Figure 62. China Axial Spondyloarthritis Drugs Revenue Market Share by Company in 2024
Figure 63. China Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
Figure 65. China Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
Figure 67. APAC Axial Spondyloarthritis Drugs Sales Quantity Market Share by Company in 2024
Figure 68. APAC Axial Spondyloarthritis Drugs Revenue Market Share by Company in 2024
Figure 69. APAC Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
Figure 71. APAC Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
Figure 73. APAC Axial Spondyloarthritis Drugs Revenue Share by Region (2018-2034)
Figure 74. APAC Axial Spondyloarthritis Drugs Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. India Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Axial Spondyloarthritis Drugs Revenue Share by Country (2018-2034)
Figure 88. Brazil Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Axial Spondyloarthritis Drugs Revenue (2018-2034) & (US$ Million)
Figure 93. Axial Spondyloarthritis Drugs Value Chain
Figure 94. Axial Spondyloarthritis Drugs Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed